We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
26
May 2026
A small clinical trial led by Dana-Farber Cancer Institute researchers put a Salk Institute idea to the test in patients: that activating the vitamin D receptor can help reshape the protective environment surrounding pancreatic tumors in ways that could make the notoriously difficult-to-treat cancer more vulnerable to therapeutic treatments.
26
May 2026
University of Rochester Medicine is in the spotlight at a national meeting for a new discovery in integrative oncology: A special yoga intervention, the study shows, goes a step further than other side-effect therapies to improve four domains of physical and psychological side effects that most patients experience, including lifting mood and easing anxiety.
26
May 2026
Stopping cancer from coming back is the goal of new research from MUSC Hollings Cancer Center, where scientists are targeting cells that fuel the return of an aggressive pediatric brain tumor.
26
May 2026
Recent advances in artificial intelligence have enabled Southwest Research Institute (SwRI) to identify nearly two dozen antiviral compounds that could potentially treat a rare species of Ebola virus (Bundibugyo virus) currently affecting the Democratic Republic of Congo.